Compugen Ltd. (CGEN)

3.30
0.05 1.50
NASDAQ : Health Technology
Prev Close 3.25
Open 3.25
Day Low/High 3.25 / 3.35
52 Wk Low/High 2.25 / 5.40
Volume 41.97K
Avg Volume 298.20K
Exchange NASDAQ
Shares Outstanding 51.79M
Market Cap 163.15M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen Announces Exclusive License Agreement With MedImmune For The Development Of Bi-Specific And Multi-Specific Antibody Products

Compugen Announces Exclusive License Agreement With MedImmune For The Development Of Bi-Specific And Multi-Specific Antibody Products

Compugen will receive $10 million upfront, and is eligible for milestone payments and royalties on any products developed under the license

Compugen Announces Publication Of The Discovery Of ILDR2 As A Novel Immune Checkpoint And Its Use For The Treatment Of Autoimmune Diseases In Two Back-to-Back Papers In The Journal Of Immunology

Compugen Announces Publication Of The Discovery Of ILDR2 As A Novel Immune Checkpoint And Its Use For The Treatment Of Autoimmune Diseases In Two Back-to-Back Papers In The Journal Of Immunology

ILDR2 forms the basis of ILDR2-Fc fusion protein, also known as CGEN-15001, Compugen's product candidate for the treatment of autoimmune diseases

Compugen Presents New Preclinical Data Demonstrating The Distinctive Features Of The PVRIG Pathway In Immuno-Oncology And The Potential Of COM701 For Treating Multiple Solid Tumors

Compugen Presents New Preclinical Data Demonstrating The Distinctive Features Of The PVRIG Pathway In Immuno-Oncology And The Potential Of COM701 For Treating Multiple Solid Tumors

Data Further Strengthens Compugen's Rationale for Clinical Development Planand Biomarker Strategy for COM701

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Compugen Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen is Now Oversold (CGEN)

Compugen is Now Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Compugen (CGEN)

Oversold Conditions For Compugen (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Compugen

Relative Strength Alert For Compugen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual...

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr.

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the third quarter ending September 30, 2015.

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, November 3, 2015 to review third quarter 2015 results.

Compugen Discloses Antibody Drug Conjugate Program Results At The World ADC Summit In San Diego

Compugen Discloses Antibody Drug Conjugate Program Results At The World ADC Summit In San Diego

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will present the status of its predictive target discovery pipeline for novel antibody drug conjugates (ADC's),...

Compugen Discloses New Results Supporting CGEN-15052 As Novel Immune Checkpoint Target Candidate For Treatment Of Cancer

Compugen Discloses New Results Supporting CGEN-15052 As Novel Immune Checkpoint Target Candidate For Treatment Of Cancer

In a poster presentation today at The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, being held in New York City, Arthur Machlenkin, Ph.

Compugen To Present At Upcoming Immuno-Oncology And Rheumatology Conferences

Compugen To Present At Upcoming Immuno-Oncology And Rheumatology Conferences

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that aspects of its immuno-oncology programs and its lead autoimmune program will be presented at four upcoming scientific...

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.